The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Predicting local recurrence using PAM50 in postmenopausal endocrine responsive breast cancer patients.
Florian Fitzal
Honoraria - AstraZeneca
Martin Filipits
No relevant relationships to disclose
Christian Fesl
No relevant relationships to disclose
Margaretha Rudas
No relevant relationships to disclose
Peter Christian Dubsky
Research Funding - Agendia; Cividon
Rupert Bartsch
No relevant relationships to disclose
Peter Regitnig
No relevant relationships to disclose
Thomas Bauernhofer
No relevant relationships to disclose
Richard Greil
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Gerhard Leitner
No relevant relationships to disclose
Michael Knauer
Research Funding - Agendia
Michael Hubalek
Honoraria - AstraZeneca
Michael A. Fridrik
No relevant relationships to disclose
Walter Herz
No relevant relationships to disclose
Otto Dietze
No relevant relationships to disclose
John W Cowens
Employment or Leadership Position - NanoString Technologies
Stock Ownership - NanoString Technologies
Sean Ferree
Employment or Leadership Position - NanoString Technologies
Stock Ownership - NanoString Technologies
Torsten O. Nielsen
Consultant or Advisory Role - NanoString Technologies
Michael Gnant
Consultant or Advisory Role - Accelsiors; AstraZeneca; Novartis
Honoraria - Amgen; AstraZeneca; GlaxoSmithKline; NanoString Technologies; Novartis; Roche
Research Funding - GlaxoSmithKline; Pfizer; Roche; Sanofi ; Smith Medical